|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 14, 2002; DOI 10.1182/blood-2002-01-0182.
HEMATOPOIESIS
From the Department of Immunology, Institute of Basic
Medical Sciences, University of Tsukuba, and Core Research for
Evolutional Science and Technology of Japan Science and Technology,
Japan; the Department of Internal Medicine III, Akita University School
of Medicine, Japan; the Molecular Biology Institute, Department of
Molecular and Medical Pharmacology, and Howard Hughes Medical
Institute, UCLA School of Medicine, Los Angeles, CA; and the Laboratory
of Stem Cell Therapy, Center for Experimental Medicine, The Institute
of Medical Science, University of Tokyo, Japan.
In the search for genes expressed in hematopoietic stem cells, we
identified that the expression of Gfi-1B (growth factor independence-1B) is highly restricted to hematopoietic stem cells, erythroblasts, and megakaryocytes. Gfi-1 and Gfi-1B are zinc finger proteins that share highly conserved SNAG and 6 zinc finger domains. Gfi-1 has been characterized as an oncogene involved in
lymphoid malignancies in mice. In contrast, role of Gfi-1B in
hematopoiesis has not been well characterized. In this study, we
analyzed its function in human hematopoiesis. Enforced expression of
Gfi-1B in human CD34+ hematopoietic progenitors
induced a drastic expansion of erythroblasts in an
erythropoietin-independent manner. Expression of
Gfi-1B did not promote erythroid commitment, but enhanced
proliferation of immature erythroblasts. Erythroblasts expanded by
exogenous Gfi-1B, however, failed to differentiate
beyond proerythroblast stage and showed massive apoptosis. These
biologic effects of Gfi-1B were mediated through its zinc finger
domain, but not by the SNAG or non-zinc finger domain. Proliferation
of erythroblasts was associated with sustained expression of GATA-2 but
not of GATA-1, indicating a potential link between Gfi-1B and GATA
family regulators. Importantly, the function of Gfi-1B to modulate
transcription was dependent on promoter context. In addition,
activation of transcription of an artificial promoter was mediated
through its zinc finger domain. These findings establish Gfi-1B as a
novel erythroid regulator and reveal its specific involvement in the regulation of erythroid cell growth through modulating
erythroid-specific gene expression.
(Blood. 2002;100:2769-2777) Gfi-1 and Gfi-1B are highly related zinc finger
proteins whose expression is exclusive to hematopoietic
cells.1,2 Both genes share highly conserved SNAG
(Snail/Gfi-1) and 6 C2-H2 zinc finger domains
in the N and C terminus, respectively. The SNAG domain is also found in
Snail/Slug zinc finger proteins and has been characterized as a
transcriptional repression domain.3,4 Random
oligonucleotide selection studies demonstrated that Gfi-1 and
Gfi-1B bind the same DNA sequence,
TAAATCAC(A/T)GC(A/T).2,5 So far only a limited number of
direct target genes have been identified, Bax for Gfi-1 and
p21Cip1/Waf,1 Socs1, and
Socs3 for Gfi-1B. In these cases, Gfi-1 and Gfi-1B act as
transcriptional repressors.2,6,7
The Gfi-1 gene was originally identified as a common
integration site of Moloney murine leukemia virus (MoMuLV) in rat
T-cell-lymphoma cell lines.1 Gfi-1 allows interleukin 2 (IL-2)-dependent T cells to escape G1 arrest induced by
IL-2 withdrawal in culture.1 Gfi-1 has also been reported
to be involved in oncogenesis. Lymphomas arising in MoMuLV-inoculated
Eµ/myc and Eµ/pim-1 transgenic mice harbor a
provirus insertion in the Gfi-1 locus, indicating that Gfi-1 acts as a dominant oncogene and collaborates with
c-myc, an HLH-LZ transcription factor, and
pim-1, a cytoplasmic serine/threonine kinase for the
induction of retrovirus-induced lymphomas in mice.8 Recently, Gfi-1 was found to directly interact with PIAS3, an inhibitory regulator of signal transducers and activators of
transcription 3 (STAT3), and affects its function, leading to an
enhancement of STAT3-mediated transcriptional activation.9
This finding may explain in part the positive effect of Gfi-1 on cell
proliferation and its oncogenic properties.
The Gfi-1B gene was cloned from its high degree of
nucleotide sequence similarity to the Gfi-1
gene.2 Gfi-1B shares the SNAG and 6 zinc finger domains
with Gfi-1 (86% and 88% identity at the amino acid level,
respectively). However, the interviewing region between the 2 conserved
domains shows a very low similarity to Gfi-1 (21% identity at the
amino acid level). Gfi-1B is expressed in the bone marrow
and spleen in mice whereas the chicken Gfi-1B homologue is
reportedly restricted to erythroid cells.10 Sustained expression of Gfi-1B inhibits IL-6-induced G1 arrest and
myeloid differentiation of the myelomonocytic cell line M1 through
direct transcriptional repression of the cyclin-dependent kinase
inhibitor p21Cip1/Waf1.2 In
contrast with Gfi-1, however, information on the function of Gfi-1B is
limited and has not yet been characterized in primary hematopoietic cells.
In the search for genes expressed in hematopoietic stem cells, we
identified that Gfi-1B is preferentially expressed in
hematopoietic stem cells, erythroblasts, and megakaryocytes. To further
understand the role of Gfi-1B in hematopoiesis, we used pseudo-type
retroviruses to introduce Gfi-1B into human primary
hematopoietic progenitors. Gfi-1B expression induced a
drastic expansion of erythroblasts in an erythropoietin
(EPO)-independent manner as well as inhibition of myeloid cell
differentiation. These effects were mediated through the highly
conserved zinc finger domain. In addition, proliferation of
erythroblasts was associated with a strong transactivating capacity of
Gfi-1B mediated through its zinc finger domain. These observations
imply novel roles of Gfi-1B in erythroid expansion in the early stage
of erythropoiesis.
Plasmids
Production of retrovirus
Purification of human primary cells Human umbilical cord blood samples were obtained, with informed consent, from placentas of full-term healthy newborn infants. Peripheral blood (PB) samples were obtained from healthy volunteers who had given informed consent. After isolation of mononuclear cells by density gradient centrifugation, CD34+ hematopoietic progenitors were obtained using magnetic bead separation (Miltenyi Biotech, Bergisch Gladbach, Germany). In all experiments, 95% of purified cells were positive for CD34 as assessed by specific antibodies.11 Informed consent was provided according to the Declaration of Helsinki. This study was approved by the institutional review committees of the University of Tsukuba.Transduction of CD34+ cells CD34+ cells were prestimulated in Iscove modified Dulbecco medium (IMDM; Sigma, St Louis, MO) supplemented with 10% fetal bovine serum (FBS), 50 ng/mL stem cell factor (SCF), 50 ng/mL thrombopoietin (TPO; kindly provided by KIRIN, Tokyo, Japan), 50 ng/mL interleukin 6 (IL-6; Peprotech, Rocky Hill, NJ), and 50 ng/mL Flt-3 ligand (Peprotech) for 20 hours. After replating onto recombinant fibronectin fragment-coated culture dishes (Takara Shuzo, Otsu, Japan) containing virus supernatant and 5 µg/mL protamine sulfate (Sigma), cells were centrifuged at 1000g for 30 minutes. Transduction was repeated with fresh virus supernatant every 12 hours, 3 times. At 60 hours after the first transduction, cells were stained with phycoerythrin (PE)-conjugated anti-CD34 (PharMingen, San Diego, CA). Cells positive for both CD34 and EGFP, or for CD34, EGFP, and NGFR, were selected by cell sorting on a FACS Vantage (Becton Dickinson, San Jose, CA) and subjected to subsequent analyses. At this time point, more than or equal to 85% of the cells were still positive for CD34.11 To detect the expression of tNGFR on the cell surface, cells were stained with mouse anti-human NGFR (Chemicon, Temecula, CA) followed by PE-conjugated rabbit anti-mouse immunoglobulin (DAKO, Glostrup, Denmark).Colony assay and in vitro liquid culture CD34+ cells transduced with indicated retroviruses were plated in methylcellulose medium (Stem Cell Technologies, Vancouver, BC, Canada) or cultured in IMDM with 10% FBS supplemented with 50 ng/mL SCF, IL-3, granulocyte macrophage-colony-stimulating factor (GM-CSF; Peprotech), and 5 U/mL erythropoietin (EPO; kindly provided by Chugai Pharmaceutical, Tokyo, Japan). The culture dishes were incubated at 37°C in a 5% CO2 atmosphere. Colony numbers were counted on day 14. Erythroid cell maturation was evaluated by benzidine staining.Flow cytometric analysis Expression of cell-surface antigens and cytoplasmic proteins was analyzed on a FACS Vantage. To detect cell-surface antigens, cells were stained with allophycocyanin (APC)-conjugated anti-human CD11b (PharMingen), PE-conjugated anti-human CD15 (Immunotech, Marseille, France), CD14, and Glycophorin A (PharMingen). Cells that stained with propidium iodide (PI) were gated out as dead cells.Cells and ex vivo generation of erythroid progenitor cells After isolation of mononuclear cells from bone marrow (BM) and PB, human hematopoietic cells were fractionated by cell sorting on a FACS Vantage. Murine hematopoietic cells fractionation and ex vivo differentiation of human erythroid progenitors were performed as previously described.13,14 In brief, human granulocyte colony-stimulating factor (G-CSF; Chugai Pharmaceutical and Kyowa Hakko Pharmaceutical, Tokyo, Japan) was administered to healthy Japanese volunteers who had previously signed consent forms approved by the Hokkaido University School of Medicine and the Hokkaido Red Cross Blood Center Committee for the Protection of Human Subjects. Mobilized PB CD34+ cells were isolated using immunomagnetic beads. Cells were then cryopreserved and stored until use in liquid nitrogen. Frozen PB CD34+ cells were thawed and cultured in serum-containing medium with IL-3 at 100 U/mL, SCF at 100 ng/mL, and EPO at 4 U/mL at 37°C in a 5% CO2.Reverse transcription-polymerase chain reaction (RT-PCR) Total RNA was isolated using ISOGEN-LS solution (Nippon Gene, Tokyo, Japan) and reverse-transcribed using the ThermoScript RT-PCR system (Gibco BRL, Gaithersburg, MD) and oligo-dT primer. The amount of cDNA was normalized by the quantitative PCR using TaqMan rodent glyceraldehyde phosphate dehydrogenase (GAPDH) control reagent (Perkin-Elmer Applied Biosystem, Foster City, CA). Semiquantitative RT-PCR reactions were then carried out for 36 cycles using normalized cDNAs and recombinant Taq DNA polymerase. Cycling parameters were denaturation at 94°C for 20 seconds, annealing at 60°C for 20 seconds, and extension at 72°C for 30 seconds. PCR products were separated on agarose gels and visualized by ethidium bromide staining. The primer sequences were: human Gfi-1B sense primer 5'-AAC TTC GAG TGC CGC ATG TGC-3', antisense primer 5'-TGA TGA GGT TGG AGC TCT GGC-3'; human Gfi-1 sense primer 5'-TAC AAG TGC ATC AAG TGC AGC-3', antisense primer 5'-TTG TGA AGC TTC TCA CCA GTG-3'; human SCL sense primer 5'-ATG ACC TCC TGC AAG ACG TGC-3', antisense primer 5'-CTG ATC TCC TAC TGG TAC AGG-3'; human GATA-1 sense primer 5'-TCA ATT CAG CAG CCT ATT CC-3', antisense primer 5'-TTC GAG TCT GAA TAC CAT CC-3'; human GATA-2 sense primer 5'-TGT TGT GCA AAT TGT CAG ACG-3', antisense primer 5'-CAT AGG TGC CAT GTG TCC AGC-3'; human Bcl-xL sense primer 5'-TTC AGT GAC CTG ACA TCC CAG-3', antisense primer 5'-TGC ATT GTT CCC ATA GAG TTC C-3': human hypoxanthine phosphoribosyltransferase (Hprt) sense primer 5'-AAG GAC CCC ACG AAG TGT TGG-3', antisense primer 5'-AGG GAA CTG ATA GTC TAT AG-3'; mouse Gfi-1B sense primer 5'-TTG GAG CAG CAT ACT CAC GTC-3', antisense primer 5'-AGA TTG TGT TGA CTC TCA CG-3'; mouse Gfi-1 sense primer 5'-AGA GCT TCA AGA GGT CAT CC-3', antisense primer 5'-TTG AGT CCA TGC TGA GTC TC-3'; mouse Hprt sense primer 5'-GCT GGT GAA AAG GAC CTC T-3', antisense primer 5'-CAC AGG ACT AGA ACA CCT GC-3'.Apoptosis assay Cells were stained with PI and biotinylated anti-Annexin V (PharMingen), followed by APC-conjugated streptavidin (PharMingen). Apoptosis was measured on a FACS Vantage as PI-negative and Annexin V-positive cells.Reporter construct and luciferase assay A tetramer oligonucleotide containing a consensus Gfi-1 binding site (CACACCAAATCACTGC)2 was subcloned into the enhancerless pT81 luciferase vector in front of a minimal herpes simplex thymidine kinase promoter.15 The SOCS-1 promoter (bp 2438 to +639) was kindly provided by Dr H. Wu.7 A
cytomegalovirus (CMV)-driven Renilla luciferase control
reporter plasmid (pRL-CMV; Promega, Madison, WI) was used as an
internal control for transfection efficiency in all transfection
experiments. Suspension cells (1 × 107
cells/transfection) were transiently transfected by electroporation as
previously described.16 Briefly, transfection was carried out by electroporation using 5 µg reporter construct, 5 µg each expression construct or empty vector, and 10 ng of an internal control
plasmid (pRL-CMV), with the total amount of DNA brought up to 20 µg
with carrier plasmid. K562 and U937 cells were electroporated at 250 volts, 960 µF, and 300 volts, 960 µF, respectively. NIH3T3 cells
were transiently transfected using Lipofectamine PLUS reagent (Gibco
BRL). Cells (3 × 104) were plated in 24-well tissue
culture plates 16 hours before transfection. The cells were then
transfected with 200 ng reporter construct, plus or minus 40 ng of each
expression construct or empty vector, 200 pg internal control plasmid
(pRL-CMV), 1 µL Lipofectamine, and 4 µL PLUS reagent for 3 hours in
serum-free medium. After 3 hours, serum was added to a final
concentration of 10%. The cells were harvested 24 hours after the
beginning of transfection. Firefly luciferase activities from the
reporter plasmids and Renilla luciferase activities from the
internal control plasmid pRL-CMV were determined using the
Dual-Luciferase Reporter Assay System (Toyo Inki, Tokyo, Japan).
Firefly luciferase values were normalized to the Renilla
luciferase values of pRL-CMV.
Restricted expression of Gfi-1B in erythroid and megakaryocytic lineages While searching for transcriptional regulators expressed in mouse hematopoietic stem cells, we identified Gfi-1B as a candidate gene. RT-PCR analysis revealed that a significant amount of Gfi-1B mRNA is expressed in mouse hematopoietic stem cells and erythroid cells. This expression profile of Gfi-1B was quite similar to those of SCL and GATA-2, important regulators for hematopoiesis (Figure 1B). In humans, Gfi-1B was up-regulated in both erythroid and megakaryocytic lineages (Figure 1A). In an ex vivo model of expansion of human erythroblasts (see "Materials and methods"), Gfi-1B expression was up-regulated as the population of erythroid cells increased during culture, and was maintained throughout successive differentiation stages from erythroid-blast-forming units (BFU-Es) to mature erythroblasts (Figure 1C). Notably, the expression profile of Gfi-1B was well correlated with that of GATA-1 during erythroid differentiation. On the other hand, expression of the related family member Gfi-1 was relatively ubiquitous in hematopoietic cells (Figure 1A-B). However, Gfi-1 was not expressed in human megakaryocytes, and its expression was much weaker than that of Gfi-1B in human erythroblasts (Figure 1A,C).
Enforced expression of Gfi-1B supports EPO-independent erythropoiesis Preferential expression of Gfi-1B in the erythroid lineage is consistent with the finding that the chicken Gfi-1B homologue is restricted to erythroid cells.10 However, the function of Gfi-1B in hematopoiesis has not yet been characterized. To understand the roles of Gfi-1B in hematopoiesis, we used retroviruses to introduce Gfi-1B into human primary CD34+ hematopoietic progenitors. We transduced cells with the retroviral vector GCsam-Gfi-1B-IRES-EGFP, which drives expression of both Gfi-1B and EGFP from a single bicistronic message. In our earlier studies using the same retroviral transduction system, we demonstrated that both erythroid and myeloid progenitor cells are transduced with similar efficiencies, and that the expression of transduced genes are high in both lineages as judged by EGFP expression.17 After transduction, cells positive for both CD34 and EGFP were selected by cell sorting and subjected to in vitro assays. Unexpectedly, CD34+ cells transduced with Gfi-1B gave rise to erythroblast colonies in the absence of EPO (Figure 2A). Although the frequency of these erythroblast colonies was 5-fold lower than that of control erythroid bursts generated in the presence of EPO (Figure 2A, left and middle panels vs right panel), they were much larger than the control erythroid bursts and were barely hemoglobinized (Figure 2B, left panel). Cytologic analysis revealed that they comprised immature erythroblasts arrested at the proerythroblast stage (Figure 2B, right panel). In the presence of EPO, Gfi-1B-transduced cells gave rise to a comparable number of erythroid bursts to the control (Figure 2A, right panel), indicating that Gfi-1B does not affect erythroid commitment. However, they still formed some large erythroblast colonies that were poorly hemoglobinized even in the presence of EPO (data not shown). Generation of erythroblast colonies from Gfi-1B-transduced cells was completely dependent on GM-CSF (Figure 2A) and to a lesser extent on IL-3 (data not shown). In contract, Gfi-1B-transduced cells gave rise to fewer myeloid colonies than the control (Figure 2A). In addition, the myeloid colonies from Gfi-1B-transduced cells were much smaller than control (data not shown).
We next analyzed the differentiation of transduced cells in liquid culture (Figure 2C). As expected from the colony assay data, Gfi-1B-transduced cells showed an expansion of glycophorin A+ erythroblasts in an EPO-independent manner. Even in the presence of EPO, they generated more erythroblasts than the control. On the contrary, development of CD15+ granulocytes and CD14+ monocytes/macrophages were repressed by enforced Gfi-1B expression. Colony assays of cells cultured in EPO-free media at days 10 and 14 revealed that Gfi-1B-transduced cells still contained a significant number of BFU-Es and erythroid-colony-forming units (CFU-Es) compared with the control (data not shown). Enforced expression of Gfi-1 showed biologic effects similar to those of Gfi-1B, indicating a redundancy in function of the 2 molecules in vitro (Figure 2C). Gfi-1B promotes erythroblast proliferation but not differentiation The observation that Gfi-1B did not affect erythroid commitment prompted us to check the effect of Gfi-1B on cell growth. In the presence of SCF and GM-CSF, Gfi-1B-transduced cells showed slightly elevated cell growth compared with the control, but the cell number reached its plateau around day 10 of culture (Figure 3A). As shown in Figure 2, Gfi-1B-transduced cells preferentially generated erythroblasts at the proerythroblast stage, whereas the control cells differentiated into myeloid cells (Figure 3B). Unexpectedly, Gfi-1B-expressing cells demonstrated more apoptosis than the control, and apoptotic cell death became prominent after day 10 of culture (Figure 3C). During ex vivo erythroid differentiation from CD34+ progenitors, Bcl-xL expression was up-regulated on day 10 of culture (Figure 1C). However, erythroblasts derived from Gfi-1B-transduced CD34+ cells failed to express a significant amount of Bcl-xL mRNA. Therefore, we cotransduced Bcl-xL with Gfi-1B into CD34+ cells. Exogenous Bcl-xL efficiently rescued cells from apoptosis and facilitated increased proliferation of Gfi-1B-expressing erythroblasts (Figure 3A-C). In addition, a significant number of rescued erythroblasts differentiated beyond the proerythroblast stage (Figure 3D). On the other hand, addition of EPO was not effective in preventing apoptosis but promoted differentiation (Figure 3C-D). In contrast, cotransduction of Bcl-xL in combination with EPO supplementation efficiently rescued apoptosis and further promoted differentiation (Figure 3C-D).
Next, we further analyzed the effect of Gfi-1B on erythroid
differentiation. Glycophorin A+ erythroblasts were
collected by cell sorting, and then hemoglobin production was evaluated
by benzidine staining (Figure 4).
Erythroblasts differentiated from Gfi-1B-transduced
CD34+ cells barely produced hemoglobin in the absence of
EPO, whereas prevention of apoptosis by Bcl-xL allowed differentiation
and hemoglobin production. Addition of EPO also facilitated
differentiation of erythroblasts from both control and
Gfi-1B-expressing cells. These findings indicate that
Gfi-1B does not have an apparent effect on erythroid
differentiation.
The Gfi-1B zinc finger domain is essential for erythroid expansion Among the 3 Gfi-1B domains, the SNAG domain has been implicated in the transcriptional repression. To determine the domain responsible for erythroid expansion, we generated a series of Gfi-1B mutants (Figure 5A) and transduced them into CD34+ progenitor cells. As shown in Figure 5B, the zinc finger domain was essential for erythroid expansion. On the other hand, the SNAG and non-zinc finger domains did not have any significant effects on this process. The zinc finger domain is highly conserved between Gfi-1B and Gfi-1. As expected, the Gfi-1 domain responsible for erythroid expansion was also localized to its zinc finger domain (Figure 5C-D).
The zinc finger domain confers transactivating activity in erythroid cells Although Gfi-1B has been characterized as a transcriptional repressor,2 functions of transcriptional regulators in general largely rely on the context, including cell type and sequences flanking the promoter. To analyze its ability to modulate transcription, we used a reporter plasmid with 4 Gfi-1 binding sites in front of a basal thymidine kinase promoter. Gfi-1B transactivated the promoter 7.8-fold above the basal level in an erythroid cell line, K562, 2.5-fold in NIH3T3 fibroblasts, and 1.9-fold in a myeloid cell line, U937 (Figure 6A). Transfection efficiencies were approximately 9% for both K562 and U937 cells and more than 80% for NIH3T3 cells (data not shown). Analysis of Gfi-1B mutants demonstrated that the zinc finger domain acts as an activation domain whereas the SNAG and non-zinc finger domains serve as repression domains. Notably, Gfi-1B activated transcription preferentially in erythroid cells. As expected, Gfi-1 exhibited similar profiles of transactivation of this artificial promoter (data not shown).
As reported, however, Gfi-1B behaved as a repressor of the SOCS-1 promoter that contains 2 Gfi-1B binding sites (Figure 6B).7 In K562 cells that express endogenous Gfi-1B, exogenous Gfi-1B did not affect the SOCS-1 promoter activity, but the introduction of mutations in both Gfi-1B binding sites led to higher SOCS-1 promoter activity (more than 2-fold). In contrast, exogenous Gfi-1B clearly repressed the SOCS-1 promoter in NIH3T3 cells, which do not express endogenous Gfi-1B. Analysis of Gfi-1B mutants demonstrated that the SNAG domain serves as a transcriptional repression domain. Deletion of the SNAG domain resulted in loss of repression in NIH3T3 cells and in partial derepression in K562 cells. The zinc finger domain did not activate transcription of the SOCS-1 promoter. These data establish that the function of Gfi-1B to modulate transcription is dependent on both the promoter and cell type context. Effect of Gfi-1B on the expression of genes involved in erythropoiesis To obtain an insight into the role of Gfi-1B in erythropoiesis, we analyzed the effect of Gfi-1B on the expression of well-known erythroid regulators. RT-PCR analysis revealed that enforced expression of Gfi-1B induces sustained expression of GATA-2 but not GATA-1 (Figure 7), indicating a potential link between Gfi-1B and GATA family regulators.
In this study, we first analyzed the detailed expression of Gfi-1B and Gfi-1 in hematopoietic cells (Figure 1). Both Gfi-1B and Gfi-1 are expressed in hematopoietic stem and progenitor cells. Among the various cell lineages, however, Gfi-1 is broadly expressed, whereas Gfi-1B is specifically expressed in erythroid cells and megakaryocytes. Throughout human erythroid differentiation, mRNA expression of Gfi-1B is maintained at a high level. These expression profiles indicate lineage-specific involvement of Gfi-1B in hematopoiesis. To investigate the roles of Gfi-1B in hematopoiesis, we overexpressed
Gfi-1B in human CD34+ hematopoietic progenitor
cells. In the absence of EPO, hematopoietic progenitors did not form
erythroblast colonies. In contrast, CD34+ progenitors
transduced with Gfi-1B gave rise to a number of large erythroid colonies in response to GM-CSF in an EPO-independent manner
(Figure 2A-B). Importantly, there was no difference in frequency of
erythroid colony formation between the control and Gfi-1B-transduced cells in the presence of EPO (Figure 2A,
right panel), indicating that Gfi-1B does not affect erythroid
commitment but rather promotes erythroblast proliferation. At a stage
prior to hemoglobin synthesis, erythroid cells can be categorized as either BFU-Es or CFU-Es. BFU-Es can be further classified as immature or mature BFU-Es according to their proliferative capacity and responsiveness to EPO.18-20 Human immature BFU-Es have few
EPO receptors and are not responsive to EPO, whereas mature BFU-Es express low levels of EPO receptors and are weakly responsive to EPO.
These cells give rise to CFU-Es that are highly responsive to
EPO.18 BFU-Es require the growth factors such as IL-3,
GM-CSF, and SCF to develop into CFU-Es.19,20 Given the
GM-CSF-dependent but EPO-independent proliferation of erythroblasts in
response to expression of exogenous Gfi-1B, it is
conceivable that Gfi-1B is involved in the mitogenic signaling pathway
activated by EPO and is responsible for cell growth of early
erythroblasts at the transition from mature BFU-Es to CFU-Es (Figure
8). In contrast to EPO, however, the
function of Gfi-1B seems to be specific to cell proliferation. We could
not detect any positive effect of Gfi-1B on erythroid differentiation
or survival (Figures 3 and 4). The specific function of Gfi-1B on cell
proliferation evokes the possibility that Gfi-1B is involved in the
JAK2/STAT signaling pathway, which is the major mitogenic signaling
pathway activated by both EPO and GM-CSF.
Importantly, enforced expression of Gfi-1B induced sustained mRNA expression of GATA-2, but not of GATA-1 in erythroblasts. This might be in part due to the accumulation of erythroid progenitor cells that are GATA-2-positive. However, the possibility that Gfi-1B positively regulates GATA-2 expression is intriguing to pursue. GATA-2 is preferentially expressed in hematopoietic stem and progenitor cells and is essential for their expansion.21 It promotes proliferation of erythroid progenitors and blocks their differentiation.22 On the other hand, GATA-1 is required for terminal maturation and survival of erythroid cells beyond the proerythroblast stage23,24 and negatively regulates cell cycle.25-27 A complex regulatory network between GATA-1 and GATA-2 has been postulated, in which GATA-1 represses GATA-2 expression during erythroid differentiation.28 Taken together, sustained expression of GATA-2 may explain in part the high mitogenic activity of Gfi-1B-expressing erythroblasts. A database search revealed 2 potential Gfi-1B binding sites in intron 1 of the mouse GATA-2 gene, but no corresponding site in the human GATA-2 gene. The possibility that Gfi-1B directly regulates GATA-2 gene expression remains to be determined. On the other hand, it is also possible that Gfi-1B negatively regulates GATA-1 function, which results in derepression of GATA-2 and relief from cell cycle repression by GATA-1. Sustained expression of GATA-2 is indicative of a potential link between Gfi-1B and GATA family regulators. Notably, erythroblasts expressing Gfi-1B failed to differentiate beyond the proerythroblast stage and showed massive apoptosis after 7 to 10 days of culture (Figure 3). They did not show up-regulation of Bcl-xL mRNA (Figure 7). Coexpression of Bcl-xL with Gfi-1B efficiently rescued erythroblasts from apoptosis, revealing an even higher mitogenic effect of Gfi-1B on erythroblasts (Figure 3A-C). In addition, expression of Bcl-xL allowed erythroblasts to further differentiate beyond the proerythroblast stage (Figure 3D). A database search revealed no potential Gfi-1B binding sites in the proximal promoters of human and murine Bcl-xl genes. Therefore, it is unlikely that Gfi-1B directly regulates Bcl-xl gene expression. It has been reported that GATA-1 and EPO cooperate to promote erythroid cell survival by regulating Bcl-xL expression.29 Erythroblasts expressing Gfi-1B showed normal GATA-1 expression (Figure 7) and EPO-responsiveness in terms of growth and differentiation (Figures 2A and 4) but did not up-regulate Bcl-xL mRNA. Taken together, there remains a possibility that Gfi-1B represses GATA-1 function as discussed above. An alternative interpretation is that the observed apoptosis occurs due to hyperproliferative signals triggered by Gfi-1B. p53 provides an "oncogene checkpoint" function that guards cells against hyperproliferative signals.30 When proliferative signals exceed a critical threshold, the alternative reading frame (ARF)-dependent checkpoint is activated, and ARF triggers a p53-dependent response that induces growth arrest and/or apoptosis. Massive apoptosis of erythroblasts could be associated with deregulated cell cycle progression induced by excessive Gfi-1B protein. However, ARF/INK4a was not up-regulated in erythroblasts expressing Gfi-1B. In addition, p21Cip1/Waf1, which is induced by p53, was not up-regulated either (data not shown). The mechanisms responsible for apoptosis and failure in Bcl-xL up-regulation remain to be determined. Gfi-1 and Gfi-1B have been characterized as transcriptional repressors. The SNAG domain functions as a transcriptional repression domain and is responsible for both Gfi-1-mediated inhibition of G1 arrest induced by IL-2 withdrawal in T cells3 and Gfi-1B-mediated inhibition of IL-6-induced G1 arrest and differentiation of M1 myeloid cells.2 Recently, the non-zinc finger domain of Gfi-1 has been demonstrated to directly interact with PIAS3, an inhibitory regulator of STAT3, and enhance STAT3-mediated transcriptional activation.9 In terms of erythroid expansion induced by Gfi-1B and Gfi-1, however, the SNAG and non-zinc finger domains were dispensable, whereas the zinc domain was essential and sufficient (Figure 5). These data contrast with previous findings that demonstrated essential roles of the SNAG and non-zinc finger domains in Gfi-1 and /or Gfi-1B functions.2,3,9 Therefore, we analyzed the ability of Gfi-1B to modulate transcription in hematopoietic cells. In contrast with the previous data showing transcriptional repression by Gfi-1B, Gfi-1B acted as a transcriptional activator on an artificial promoter (Figure 6). Mapping the functional domains revealed that the zinc finger domain acts as an activation domain, whereas the SNAG domain serves as a repression domain, as expected, as does the non-zinc finger domain. Interestingly, the transactivation activity was significant in an erythroid cell line. On the other hand, we also confirmed that Gfi-1B behaves as a repressor of the SOCS-1 promoter, one of the well-characterized Gfi-1B target promoters. These data establish for the first time that the function of Gfi-1B to modulate transcription is dependent on both the promoter and cell type context. Although the zinc finger domain has been characterized only as a DNA binding domain,5 our findings suggest that the zinc finger domain itself could mediate or enhance mitogenic signals, possibly by activating transcription of as-not-yet-identified target genes. The fact that the zinc finger domain is highly conserved between Gfi-1 and Gfi-1B may explain the functional redundancy between Gfi-1 and Gfi-1B in erythroid expansion in vitro. Another biologic phenotype induced by enforced expression of Gfi-1B, as well as Gfi-1, is suppression of myelopoiesis. In contrast with a drastic expansion of erythroblasts, development of granulocytes and macrophages was significantly inhibited. This function stands in contrast to the role of Gfi-1B in erythroid cells. Given the predominant expression of Gfi-1 but not Gfi-1B in myeloid cells, our findings suggest distinct roles of Gfi-1 from those of Gfi-1B in myeloid development. In summary, we demonstrated that Gfi-1B supports proliferation of immature erythroblasts through its zinc finger domain and regulates transcription during erythropoiesis. These findings strongly implicate involvement of Gfi-1B in normal erythropoiesis and support its potential role in hematopoietic stem cells and megakaryocytes as well (Figure 8). Note added in proof. Saleque et al31 have recently reported that Gfi-1b-deficient embryos die with failure to produce definitive enucleated erythrocytes. The fetal liver of mutant mice contains erythroid and megakaryocytic precursors arrested in their development whereas myelopoiesis is normal.
We thank Dr Yoshihiro Shiina (Shiina Hospital, Ushiku, Ibaraki, Japan) and Dr Nikunj Somia (University of Minnesota) for providing us with human cord blood and 293gp cells, respectively; Dr Daniel G. Tenen for critical reading of the manuscript; Yohei Morita for technical assistance; and Miss Michie Itoh for excellent secretarial assistance.
Submitted January 23, 2002; accepted June 4, 2002.
Prepublished online as Blood First Edition Paper, June 14, 2002; DOI 10.1182/blood-2002-01-0182.
Supported in part by grants from the Ministry of Education, Culture, Sport, Science and Technology, and Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Corporation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Atsushi Iwama and Hiromitsu Nakauchi, Laboratory of Stem Cell Therapy, Center for Experimental Medicine, The Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan; e-mail: aiwama{at}ims.u-tokyo.ac.jp, or nakauchi{at}ims.u-tokyo.ac.jp.
1.
Gilks CB, Bear SE, Grimes HL, Tsichlis PN.
Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein.
Mol Cell Biol.
1993;13:1759-1768
2.
Tong B, Grimes HL, Yang T-Y, et al.
The Gfi-1B proto-oncoprotein repress p21WAF1 and inhibits myeloid cell differentiation.
Mol Cell Biol.
1998;18:2462-2473 3. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. Mol Cell Biol. 1996;16:6263-6272[Abstract]. 4. Hemavathy K, Guru SC, Harris J, Chen JD, Ip YT. Human slug is a repressor that localizes to sites of active transcription. Mol Cell Biol. 2000;26:5087-5095. 5. Zweidler-McKay PA, Grimes HL, Flubacher MM, Tsichlis PN. Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Mol Cell Biol. 1996;16:4024-4034[Abstract].
6.
Grimes HL, Gilks CB, Chan TO, Porter S, Tsichlis PN.
The Gfi-1 proto-oncoprotein represses Bax expression and inhibits T-cell death.
Proc Natl Acad Sci U S A.
1996;93:14569-14573
7.
Jegalian AG, Wu H.
Regulation of SOCS gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin.
J Biol Chem.
2002;277:2345-2352 8. Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B, Jonkers J. Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res. 1999;59:1773s-1777s[Medline] [Order article via Infotrieve]. 9. Rödel B, Tavassoli K, Karsunky H, et al. The zinc finger protein Gfi-1 can enhance STAT3 signaling by interacting with the STAT3 inhibitor PIAS3. EMBO J. 2000;19:5845-5855[CrossRef][Medline] [Order article via Infotrieve]. 10. Fuchs B, Wagner T, Rössel N, Antoine M, Beug H, Niessing J. Structure and erythroid cell-restricted expression of a chicken cDNA encoding a novel zinc finger protein of the Cys + His class. Gene. 1997;195:277-284[CrossRef][Medline] [Order article via Infotrieve]. 11. Kaneko S, Onodera M, Fujiki Y, Nagasawa T, Nakauchi H. Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. Hum Gene Ther. 2001;12:35-44[CrossRef][Medline] [Order article via Infotrieve].
12.
Miller AD, Chen F.
Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry.
J Virol.
1996;70:5564-5571
13.
Osawa M, Miyoshi S, Copeland NG, et al.
Characterization of the mouse interleukin-13 receptor
14.
Oda A, Sawada K, Druker BJ, et al.
Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors.
Blood.
1998;92:443-451 15. Nordeen SK. Luciferase reporter gene vectors for analysis of promoters and enhancers. BioTechniques. 1988;6:454-458[Medline] [Order article via Infotrieve].
16.
Iwama A, Pan J, Zhang P, et al.
Dimeric RFX proteins contribute to the activity and lineage-specificity of the IL-5R
17.
Iwama A, Osawa M, Hirasawa R, et al.
Reciprocal roles for C/EBP and PU.1 transcription factors in Langerhans cell commitment.
J Exp Med.
2002;195:547-558 18. Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement of erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol. 1974;83:309-320[CrossRef][Medline] [Order article via Infotrieve].
19.
Gregory CJ, Eaves AC.
Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses.
Blood.
1977;49:855-864
20.
Gregory CJ, Eaves AC.
Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties.
Blood.
1978;51:527-537 21. Tsai FY, Keller G, Kuo FC, et al. An early hematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371:221-226[CrossRef][Medline] [Order article via Infotrieve].
22.
Briegel K, Lim K-C, Plank C, Beug H, Engel JD, Zenke M.
Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner.
Genes Dev.
1993;7:1097-1109
23.
Shivdasani RA, Orkin SH.
The transcriptional control of hematopoiesis.
Blood.
1996;87:4025-4039 24. Orkin SH. Diversification of hematopoietic stem cells to specific lineages. Nat Rev Genet. 2000;1:57-64[CrossRef][Medline] [Order article via Infotrieve].
25.
Dubart A, Romeo PH, Vainchenker W, Dumenil D.
Constitutive expression of GATA-1 interferes with the cell-cycle regulation.
Blood.
1996;87:3711-3721 26. Whyatt DJ, Karis A, Harkes IC, et al. The level of the tissue-specific factor GATA-1 affects the cell-cycle machinery. Genes Funct. 1997;1:11-24[Medline] [Order article via Infotrieve].
27.
Vyas P, Norris FA, Joseph R, Majerus PW, Orkin SH.
Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1.
Proc Natl Acad Sci U S A.
2000;97:13696-13701
28.
Weiss MJ, Keller G, Orkin SH.
Novel insights into erythroid development revealed through in vitro differentiation of GATA-1- embryonic stem cells.
Genes Dev.
1994;8:1184-1197
29.
Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ.
GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression.
Blood.
1999;94:87-96
30.
Sherr CJ.
Tumor surveillance via the ARF-p53 pathway.
Genes Dev.
1998;12:2984-2991
31.
Saleque S, Cameron S, Orkin SH.
The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages.
Genes Dev.
2002;16:301-306
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Ogaeri, K. Eto, M. Otsu, H. Ema, and H. Nakauchi The Actin Polymerization Regulator WAVE2 Is Required for Early Bone Marrow Repopulation by Hematopoietic Stem Cells Stem Cells, May 1, 2009; 27(5): 1120 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamazaki, A. Iwama, S.-i. Takayanagi, K. Eto, H. Ema, and H. Nakauchi TGF-{beta} as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation Blood, February 5, 2009; 113(6): 1250 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Seita, M. Asakawa, J. Ooehara, S.-i. Takayanagi, Y. Morita, N. Watanabe, K. Fujita, M. Kudo, J. Mizuguchi, H. Ema, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells Blood, February 15, 2008; 111(4): 1903 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. F. Marteijn, L. T. van der Meer, L. van Emst, S. van Reijmersdal, W. Wissink, T. de Witte, J. H. Jansen, and B. A. Van der Reijden Gfi1 ubiquitination and proteasomal degradation is inhibited by the ubiquitin ligase Triad1 Blood, November 1, 2007; 110(9): 3128 - 3135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Kuo and Z.-F. Chang GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription Mol. Cell. Biol., June 15, 2007; 27(12): 4261 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Khanna-Gupta, H. Sun, T. Zibello, H. M. Lee, R. Dahl, L. A. Boxer, and N. Berliner Growth factor independence-1 (Gfi-1) plays a role in mediating specific granule deficiency (SGD) in a patient lacking a gene-inactivating mutation in the C/EBP{epsilon} gene Blood, May 15, 2007; 109(10): 4181 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xu and B. L. Kee Growth factor independent 1B (Gfi1b) is an E2A target gene that modulates Gata3 in T-cell lymphomas Blood, May 15, 2007; 109(10): 4406 - 4414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tadokoro, H. Ema, M. Okano, E. Li, and H. Nakauchi De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells J. Exp. Med., April 16, 2007; 204(4): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yasuda, K. Bundo, A. Hino, K. Honda, A. Inoue, M. Shirakata, M. Osawa, T. Tamura, H. Nariuchi, H. Oda, et al. Dok-1 and Dok-2 are negative regulators of T cell receptor signaling Int. Immunol., April 1, 2007; 19(4): 487 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Vassen, T. Okayama, and T. Moroy Gfi1b:green fluorescent protein knock-in mice reveal a dynamic expression pattern of Gfi1b during hematopoiesis that is largely complementary to Gfi1 Blood, March 15, 2007; 109(6): 2356 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. F. Marteijn, L. T. van der Meer, L. Van Emst, T. de Witte, J. H. Jansen, and B. A. van der Reijden Diminished proteasomal degradation results in accumulation of Gfi1 protein in monocytes Blood, January 1, 2007; 109(1): 100 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hosoya-Ohmura, N. Mochizuki, M. Suzuki, O. Ohneda, K. Ohneda, and M. Yamamoto GATA-4 Incompletely Substitutes for GATA-1 in Promoting Both Primitive and Definitive Erythropoiesis in Vivo J. Biol. Chem., October 27, 2006; 281(43): 32820 - 32830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Takayanagi, T. Hiroyama, S. Yamazaki, T. Nakajima, Y. Morita, J. Usui, K. Eto, T. Motohashi, K. Shiomi, K. Keino-Masu, et al. Genetic marking of hematopoietic stem and endothelial cells: identification of the Tmtsp gene encoding a novel cell surface protein with the thrombospondin-1 domain Blood, June 1, 2006; 107(11): 4317 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Acar, H. Jafar-Nejad, N. Giagtzoglou, S. Yallampalli, G. David, Y. He, C. Delidakis, and H. J. Bellen Senseless physically interacts with proneural proteins and functions as a transcriptional co-activator Development, May 15, 2006; 133(10): 1979 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Matsubara, A. Iwama, S. Yamazaki, C. Furuta, R. Hirasawa, Y. Morita, M. Osawa, T. Motohashi, K. Eto, H. Ema, et al. Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development J. Exp. Med., December 5, 2005; 202(11): 1483 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Schuh, A. J. Tipping, A. J. Clark, I. Hamlett, B. Guyot, F. J. Iborra, P. Rodriguez, J. Strouboulis, T. Enver, P. Vyas, et al. ETO-2 Associates with SCL in Erythroid Cells and Megakaryocytes and Provides Repressor Functions in Erythropoiesis Mol. Cell. Biol., December 1, 2005; 25(23): 10235 - 10250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Duan, A. Zarebski, D. Montoya-Durango, H. L. Grimes, and M. Horwitz Gfi1 Coordinates Epigenetic Repression of p21Cip/WAF1 by Recruitment of Histone Lysine Methyltransferase G9a and Histone Deacetylase 1 Mol. Cell. Biol., December 1, 2005; 25(23): 10338 - 10351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-Y. Huang, Y.-Y. Kuo, and Z.-F. Chang GATA-1 mediates auto-regulation of Gfi-1B transcription in K562 cells Nucleic Acids Res., September 21, 2005; 33(16): 5331 - 5342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lopez, L. Stuhl, S. Fichelson, A. Dubart-Kupperschmitt, R. St Arnaud, J.-R. Galindo, A. Murati, N. Berda, P. Dubreuil, and S. Gomez NACA is a positive regulator of human erythroid-cell differentiation J. Cell Sci., April 15, 2005; 118(8): 1595 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Garcon, C. Lacout, F. Svinartchouk, J.-P. Le Couedic, J.-L. Villeval, W. Vainchenker, and D. Dumenil Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells Blood, February 15, 2005; 105(4): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jafar-Nejad and H. J. Bellen Gfi/Pag-3/Senseless Zinc Finger Proteins: a Unifying Theme? Mol. Cell. Biol., October 15, 2004; 24(20): 8803 - 8812. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazanjian, D. Wallis, N. Au, R. Nigam, K. J. T. Venken, P. T. Cagle, B. F. Dickey, H. J. Bellen, C. B. Gilks, and H. L. Grimes Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells Cancer Res., October 1, 2004; 64(19): 6874 - 6882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Addya, M. A. Keller, K. Delgrosso, C. M. Ponte, R. Vadigepalli, G. E. Gonye, and S. Surrey Erythroid-induced commitment of K562 cells results in clusters of differentially expressed genes enriched for specific transcription regulatory elements Physiol Genomics, September 16, 2004; 19(1): 117 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Y. Huang, Y.-Y. Kuo, J.-S. Lai, Y. Suzuki, S. Sugano, and Z.-F. Chang GATA-1 and NF-Y cooperate to mediate erythroid-specific transcription of Gfi-1B gene Nucleic Acids Res., July 27, 2004; 32(13): 3935 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takano, H. Ema, K. Sudo, and H. Nakauchi Asymmetric Division and Lineage Commitment at the Level of Hematopoietic Stem Cells: Inference from Differentiation in Daughter Cell and Granddaughter Cell Pairs J. Exp. Med., February 2, 2004; 199(3): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wallis, M. Hamblen, Y. Zhou, K. J. T. Venken, A. Schumacher, H. L. Grimes, H. Y. Zoghbi, S. H. Orkin, and H. J. Bellen The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival Development, January 1, 2003; 130(1): 221 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
SNAG; 
stem cells,
CD34+ progenitor cells, glycophorin A (GPA)+
erythroblasts, CD41+ megakaryocytes, CD13+
myeloid progenitors, CD14+ macrophage, CD15+
granulocytes, CD56+ NK cells, and peripheral blood CD3
T+ cells, CD19+ B cells, CD4+ T
cells, and CD8+ T cells. (B) Expression of murine
Gfi-1B. Cells analyzed are bone marrow
CD34
1 gene.
Immunogenetics.
2000;51:974-981